KR20010041418A - 프로테아제-활성화되는 수용체 4 및 그것의 사용 - Google Patents

프로테아제-활성화되는 수용체 4 및 그것의 사용 Download PDF

Info

Publication number
KR20010041418A
KR20010041418A KR1020007009552A KR20007009552A KR20010041418A KR 20010041418 A KR20010041418 A KR 20010041418A KR 1020007009552 A KR1020007009552 A KR 1020007009552A KR 20007009552 A KR20007009552 A KR 20007009552A KR 20010041418 A KR20010041418 A KR 20010041418A
Authority
KR
South Korea
Prior art keywords
par4
receptor
leu
thrombin
ser
Prior art date
Application number
KR1020007009552A
Other languages
English (en)
Korean (ko)
Inventor
코우프린샤운알.
칸마크
Original Assignee
더 리젠츠 오브 더 유니버시티 오브 캘리포니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 filed Critical 더 리젠츠 오브 더 유니버시티 오브 캘리포니아
Publication of KR20010041418A publication Critical patent/KR20010041418A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
KR1020007009552A 1998-02-27 1999-02-11 프로테아제-활성화되는 수용체 4 및 그것의 사용 KR20010041418A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3239798A 1998-02-27 1998-02-27
US09/032,397 1998-02-27
PCT/US1999/002983 WO1999043809A2 (fr) 1998-02-27 1999-02-11 Recepteur 4 active par la protease et ses utilisations

Publications (1)

Publication Number Publication Date
KR20010041418A true KR20010041418A (ko) 2001-05-15

Family

ID=21864751

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020007009552A KR20010041418A (ko) 1998-02-27 1999-02-11 프로테아제-활성화되는 수용체 4 및 그것의 사용

Country Status (7)

Country Link
EP (1) EP1056854A2 (fr)
JP (1) JP2002504369A (fr)
KR (1) KR20010041418A (fr)
AU (1) AU2672899A (fr)
CA (1) CA2321142A1 (fr)
NO (1) NO20004274L (fr)
WO (1) WO1999043809A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892014A (en) 1996-10-30 1999-04-06 The Regents Of The University Of California DNA encoding a protease-activated receptor 3
US6111075A (en) * 1998-04-01 2000-08-29 Zymogenetics, Inc. Protese-activated receptor PAR4 (ZCHEMR2)
WO2000015243A1 (fr) * 1998-09-15 2000-03-23 The University Of Melbourne Methode de traitement et agents a cet effet
US7026155B2 (en) 1999-02-02 2006-04-11 Regents Of The University Of California Method of reducing bacterial proliferation
GB9925005D0 (en) 1999-10-22 1999-12-22 Univ Nottingham The treatment of wounds
WO2001058930A1 (fr) * 2000-02-09 2001-08-16 Zymogenetics, Inc. Peptides et polypeptides de par4
AU2001238366A1 (en) * 2000-02-17 2001-08-27 The Regents Of The University Of California Methods of modulating protease-activated receptor-4 (par4) activation via cathepsin
WO2001094411A1 (fr) * 2000-06-05 2001-12-13 The Regents Of The University Of California Peptides modulant des recepteurs actives par des recepteurs de protease et methodes d'utilisation
US6841354B2 (en) * 2000-12-21 2005-01-11 Philadelphia, Health & Education Corporation Screening assay for anti-thrombotic/anti-platelet activity
US7179887B2 (en) 2001-03-02 2007-02-20 Ortho-Mcneil Pharmaceutical, Inc. Guinea pig proteinase-activated receptor 4 and its activating peptide
WO2004080372A2 (fr) * 2003-03-11 2004-09-23 Bayer Healthcare Ag Diagnostic et traitement de maladies associees au recepteur 4 active par la proteinase et couple aux proteines g (par 4)
US20070243632A1 (en) 2003-07-08 2007-10-18 Coller Barry S Methods for measuring platelet reactivity of patients that have received drug eluting stents
ATE536889T1 (de) 2003-07-08 2011-12-15 Accumetrics Inc Kontrollierte thrombozyten-aktivierung zur überwachung der behandlung von adp-antagonisten
KR20100017576A (ko) * 2007-05-03 2010-02-16 아큐메트릭스, 인크. 트롬빈 수용체 길항제에 의한 혈소판 응집 억제의 측정 방법
GB2450747A (en) * 2007-07-06 2009-01-07 Univ Sheffield Treatment of sensorineural hearing loss
US8975384B2 (en) 2008-01-31 2015-03-10 Osaka University Tag peptide and use thereof
US10266488B2 (en) 2013-10-10 2019-04-23 Eastern Virginia Medical School 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase
US11319528B2 (en) 2015-07-13 2022-05-03 University Of Utah Research Foundation Methods of making red blood cells and platelets in vitro and uses thereof
KR20200063159A (ko) * 2017-09-11 2020-06-04 모나쉬 유니버시티 인간 트롬빈 수용체 par4 결합 단백질
KR20210072034A (ko) * 2018-10-05 2021-06-16 유타대학연구재단 변형된 수용체를 포함하는 혈소판을 제조하는 방법 및 이의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686597A (en) * 1995-06-06 1997-11-11 Incyte Pharmaceuticals, Inc. Thrombin receptor homolog
US5892014A (en) * 1996-10-30 1999-04-06 The Regents Of The University Of California DNA encoding a protease-activated receptor 3
WO1998031810A2 (fr) * 1997-01-21 1998-07-23 Schering Corporation Chemokines de mammiferes, recepteurs, reactifs, utilisations

Also Published As

Publication number Publication date
WO1999043809A3 (fr) 1999-10-14
NO20004274D0 (no) 2000-08-25
AU2672899A (en) 1999-09-15
NO20004274L (no) 2000-10-13
JP2002504369A (ja) 2002-02-12
CA2321142A1 (fr) 1999-09-02
EP1056854A2 (fr) 2000-12-06
WO1999043809A2 (fr) 1999-09-02

Similar Documents

Publication Publication Date Title
KR20010041418A (ko) 프로테아제-활성화되는 수용체 4 및 그것의 사용
US5892014A (en) DNA encoding a protease-activated receptor 3
JP2002532083A (ja) ４７個のヒト分泌タンパク質
EP0579739A1 (fr) Recepteurs d'interleukine 8, molecules et procedes apparentes
JP2002526059A (ja) ３１個のヒト分泌タンパク質
JP2005506037A (ja) 脊髄および脳で発現される新規なヒトイオンチャンネルをコードする新規なヒト核酸分子およびポリペプチド
JPH1175873A (ja) 新規化合物
JP2000083669A (ja) Ｃｘｃｒ４ケモカイン受容体のヒトスプライス変異体ｃｘｃｒ４ｂ
JP2000083689A (ja) シアロアドヘシンファミリ―メンバ――２（ｓａｆ―２）
WO2001007072A1 (fr) Modulation de l'activation plaquettaire
AU1449500A (en) Genes and proteins predictive and therapeutic for renal disease and associated disorders
US20080009004A1 (en) Claudin polypeptides, polynucleotides, and methods of making and use thereof
US20060286117A1 (en) Neuronally expressed stem cell factor modulates angiogenesis and neural stem cell migration to areas of brain injury
JP2002300889A (ja) クリングル関連クローン、ｈｔｈｂｚ４７
JP2000037191A (ja) ラット・カテプシンｋのポリヌクレオチドおよびポリペプチド配列
EP0887081A2 (fr) Kinase régulée par les glucocorticoides du sérum humain, une cible pour maladies rénales chroniques
JP3660880B2 (ja) 新規なチンパンジーエリスロポエチン（ｃｈｅｐｏ）ポリペプチドおよびこれをコードする核酸
JP2002530058A (ja) ３１個のヒト分泌タンパク質
CA2337835A1 (fr) Compositions de polypeptides et de polynucleotides de canaux k
JP2002186492A (ja) ヒトｒｃｅ１
JPH11113580A (ja) 新規化合物
JP2003527818A (ja) 新規なｅｓｋカリウムチャンネルのポリペプチドおよびポリヌクレオチドの組成物
CA2220955A1 (fr) Facteur de croissance des fibroblastes 13
JP2002507418A (ja) サイトカインシグナル伝達のサプレッサー
JP2002506884A (ja) Ｆａｓ関連ポリペプチド

Legal Events

Date Code Title Description
A201 Request for examination
E801 Decision on dismissal of amendment
E902 Notification of reason for refusal
E601 Decision to refuse application